

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
				SYP-159
		TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/889711
INTERNATIONAL APPLICATION NO. PCT/EP00/00689		INTERNATIONAL FILING DATE 27 JANUARY 2000	PRIORITY DATE CLAIMED 28 JANUARY 1999	
TITLE OF INVENTION METHOD AND KIT FOR IDENTIFYING OR CHARACTERISING POLYPEPTIDES				
APPLICANT(S) FOR DO/EO/US UNIVERSITY de GENEVE et al				
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). <p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail <input type="checkbox"/> Other items or information: 				

U.S. APPLICATION NO. (IF KNOWN) SEE 37 CFR 09/889711	INTERNATIONAL APPLICATION NO. PCT/EP00/00689	ATTORNEY'S DOCKET NUMBER SYP-159
--	---	-------------------------------------

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS	PTO USE ONLY
<input type="checkbox"/>	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1000.00	
<input checked="" type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$860.00	
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$710.00	
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00	
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00	

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

 20 30

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	68 - 20 =	48	x \$18.00	\$864.00
Independent claims	2 - 3 =	0	x \$80.00	\$0.00

Multiple Dependent Claims (check if applicable)**TOTAL OF ABOVE CALCULATIONS =** **\$1,994.00** Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$0.00

SUBTOTAL = **\$1,994.00** Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE = **\$1,994.00** Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$40.00

TOTAL FEES ENCLOSED = **\$2,034.00**

Amount to be: \$

Refunded \$

Charged \$

- a. A check in the amount of _____ to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. 501191 in the amount of \$2,034.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 501191. A duplicate copy of this sheet is enclosed.
- d. Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Andrew T. Karnakis, Esq.
Chief Patent Counsel
PerSeptive Biosystems, Inc.
500 Old Connecticut Path
FRAMINGHAM
MA, 01701

SIGNATURE

ANDREW T. KARNAKIS

NAME

27909

REGISTRATION NUMBER

18 July 2001

DATE

09/889711
(P)"METHOD AND KIT FOR IDENTIFYING OR CHARACTERISINGPOLYPEPTIDES"Background of the invention1. Field of the invention

This invention relates to the identification or characterisation of one or more polypeptides which have been isolated on a gel, typically from polyacrylamide gel electrophoresis (PAGE) and to a kit for use in the method. It is especially useful in proteomics (the large scale identification and characterisation of proteins).

2. Description of the related art

In proteomics, massively parallel protein identification and characterisation techniques are required. The identification of proteins or other polypeptides merely by PAGE, even using two-dimensional gels (2D-PAGE), is laborious and often uncertain. Many different methods have been developed to identify and partially characterise proteins from complex biological samples. Some of them use Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) techniques to analyse peptide "fingerprints" produced by fragmenting the proteins with enzymes. Several software programs have been developed to compare mass spectra of the peptides obtained from MALDI-TOF MS experiments with theoretical spectra from proteins. The subject has been reviewed by M. Kussmann and P. Roepstorff, Spectroscopy 1998, 14, 1-27. These authors noted three ways in which proteins separated by gel electrophoresis could be digested with enzymes to yield fragment peptides:

1. The digestion can be carried out in a plug of excised gel and the peptides recovered by elution. This is the authors' own preference.

- 2 -

2. The protein can be first electroeluted from an excised gel plug and then digested in solution.

3. The protein can be electroblotted onto a membrane and subsequently digested on the membrane.

5 These types of processes are not practical for the sequencing of polypeptides which have been run on the same gel, since the cutting out of the polypeptide bands from the gel has to be done sequentially and the plugs thus obtained placed in tubes for further analysis.

10 Also, losses occur when the polypeptides adhere to the walls of the tube.

Two of the present inventors have experimented with a different method, which they have termed one-step digestion transfer (OSDT). See US Patent Application SN 15 09/107 991 filed June 30, 1998 and corresponding Canadian Patent Application No. 2 244 947 filed September 24, 1998 entitled "Methods of identifying polypeptides", the disclosure of which is herein incorporated by reference. They have found that the proteins or other polypeptides separated on a gel can be cleaved into fragments, for example by digestion with an enzyme, and that these fragments are presented very satisfactorily for analysis, especially by MALDI-TOF MS, if the cleaving reagent is immobilised on a hydrophilic membrane and interposed as 20 the "filling" in a blotting "sandwich" between the separation gel as one "slice" of the sandwich and a hydrophobic collection member, exemplified as a conventional polyvinylidene fluoride (PVDF) membrane, as the other "slice" of the sandwich. In this way, the 25 fragments are collected on the hydrophobic member and can then be formulated in an appropriate way for the MALDI-TOF MS. It is only necessary that the transblotting is carried out so that the proteins have a long enough residence period in the proximity of the immobilised 30

- 3 -

cleaving reagent to ensure that a reasonable amount of the fragments is produced, but, of course, not so long as to allow undesired diffusion. With electroblotting, i.e. blotting assisted by an electric field, this is easily achievable by varying appropriately the current used in the electroblotting, e.g. by pulsing the current or using a unsymmetrical alternating current. Further, when an enzyme is used as the cleaving agent and when the enzyme is immobilised securely on a hydrophilic membrane, especially by covalent bonding to the solid phase, autodigestion (cleavage of the enzyme by itself) is inhibited.

The OSDT method gives good results for many proteins, but very strongly basic proteins such as lysozyme are not easily transferred under the conditions which are optimal for use of the preferred enzyme, trypsin. Trypsin gives best digestion in a buffer of pH about 8.4. Also, the OSDT method does not give good digestion of very high molecular weight proteins.

Summary of the Invention

The present invention is an improvement to the OSDT method and is based in part on the discovery of another technology which the inventors have termed "in full gel digestion" (IFG). This procedure involves dehydrating the gel and then rehydrating it, adding to gel a polypeptide-cleaving reagent such as an enzyme, e.g. in the rehydration buffer. After the IFG, the digested proteins are then electroblotted in a conventional way. One drawback of this technique is the loss of low molecular weight proteins (those of m.w. less than 40kDa) by diffusion during the in-gel digestions.

It has now been found that by combining the IFG procedure, optionally modified, with OSDT, satisfactory digestion of the proteins (or other polypeptides),

- 4 -

accompanied by improved identification, can be achieved for polypeptides having a wide range of molecular weights. Moreover, high molecular weight proteins can be satisfactorily immunoblotted to yield fragments which can
5 be identified as epitopes.

In a preferred "combined procedure", the gel is dehydrated and at least partially, preferably only partially, rehydrated with a buffer containing the polypeptide-cleaving reagent, IFG is performed and this
10 is then followed by OSDT.

In one aspect the invention provides a method of identifying or characterising polypeptides which have been isolated on a gel by electrophoresis, comprising:

- a) providing a gel on which at least one polypeptide
15 has been isolated;
- b) incorporating a first polypeptide-cleaving reagent in the gel (preferably by dehydrating the gel and at least partially rehydrating it with a buffer containing the polypeptide-cleaving reagent);
- c) providing adjacent to the gel at least one hydrophilic membrane on which is immobilised at least one second polypeptide-cleaving reagent ;
- d) providing a hydrophobic collection member (preferably a membrane) suitable for receiving thereon
20 fragments of polypeptide transferred thereto from the gel by transblotting, preferably by electroblotting, said hydrophobic member being positioned beyond the hydrophilic membrane in a direction of movement of the fragments of polypeptide;
- e) transblotting the polypeptide or polypeptides from the full gel, on which the polypeptide or polypeptides were isolated, through the hydrophilic membrane or membranes, under conditions effective to cause it or them
25
30

- 5 -

to be cleaved into fragments by the second polypeptide-cleaving reagent, to the hydrophobic member; and
f) identifying or characterising the fragments collected on the hydrophobic collection layer.

5 Preferably the method further comprises

g) identifying or characterising the polypeptide from which the fragments were derived.

The invention also includes a kit for use in the method of the invention, said kit comprising:

10 a) a first polypeptide-cleaving reagent suitable for incorporating in an electrophoretic gel;

b) at least one hydrophilic membrane suitable for use in transblotting of polypeptides separated on an electrophoretic gel, the membrane having at least one second polypeptide-cleaving reagent immobilised thereon; and

15 c) a hydrophobic collection member suitable for receiving thereon fragments of the separated polypeptides transferred thereto by transblotting.

20 Elements b) and c) may be provided as separate components, e.g. in separate containers, or as a pre-formed assembly.

The term "cleaving a polypeptide", as used herein, refers to any step in which a group, residue or any chain 25 of groups or residues is split off from the remainder of the molecule. It includes cleavage in the main chain of amino acids or in a side-chain or of any terminal or side-chain group or residue, e.g. removal of a C-terminal amino acid by carboxypeptidase, N-terminal amino group by 30 an aminopeptidase or a glycosyl side-chain by a glycosidase is included.

The method of the invention requires digestion in the full gel. That is, the method does not include

- 6 -

cutting pieces from the gel and digesting the cut pieces in an enzyme.

Reference above to the gel having been dehydrated covers allowing it to become dehydrated merely by standing in air at ambient temperature or taking deliberate steps to dehydrate it. The term "dehydration" includes complete, substantially complete or partial removal of water from the gel.

The term "collection member" as used herein has a broad meaning, since this is not in itself critical to the invention. Considered in isolation, it may be, for example, a self-supporting membrane, film, or plate, or it may be non-self-supporting, e.g. a hydrophobic layer supported on a substrate, e.g. as a coating. It will normally be porous to the blotting buffer, to enable current to be carried to or from the electrode, but may alternatively be the electrode or in direct electrical communication with it.

The term "transblotting", as used herein, covers any operation of transferring the polypeptide fragments to another surface, which, in this invention, is a hydrophobic collection member. It includes a process of transfer by capillary action or by electroblotting. In this specification, "transblotting" can be part of any blotting procedure applicable to polypeptides, including, for example immunoblotting.

The term "identifying" as used herein is not synonymous with determining the sequence and includes partially identifying the polypeptide. Further, it includes making a tentative identification based on the most probable of a small number of possibilities.

The term "kit" as used herein includes combinations of the identified components in separate containers and also an assembly of the hydrophilic membrane(s) and

- 7 -

hydrophobic collection layer ready for use. The kit may further include, in separate containers, other reagents useful in the method of the invention, e.g. a buffer for rehydrating the gel, a blotting buffer, reagent(s) which assist in the reaction of the enzyme with the polypeptide fragment and so on.

Brief description of the drawings

Figs. 1 and 2 are schematic views of two kinds of blotting "sandwich" which can be used in the invention;

Fig. 3 is a plot of applied voltage against time, showing the production of an alternating voltage for use in electroblotting in the method of the invention;

Figs. 4A-4D and 5A-5D show stained polypeptide bands present on the collection membrane to which the proteins and protein fragments have been transferred, respectively, for control (4A, 5A), IFG digestion (4B, 5B), OSDT (4C, 5C) and the combined method of the invention (4D, 5D); and

Figs. 6A-6C and 7A-7C show the MALDI-TOF MS spectra obtained from myosin and chicken lysozyme respectively, for IFG (6A, 7A), OSDT (6B, 7B) and the combined method of the invention (6C, 7C).

Description of the preferred embodiments

The invention relates to identifying polypeptide(s) which have already been isolated on a gel by gel electrophoresis. The nature of the polypeptide(s) to be identified is not critical. They can be, for example, naturally occurring proteins, proteins made by recombinant DNA technology, polypeptide(s) made by peptide synthesis or by expression of recombinant DNA. For brevity, the invention will be described hereinafter with reference to proteins. The extrapolation to other polypeptide(s) will be taken as understood and incorporated throughout the following description.

- 8 -

The kind of gel on which the proteins have been isolated is not critical, but will usually be a polyacrylamide gel. Any of the conventional gels and separation conditions may have been employed, including reducing conditions. They may be one-dimensional or two-dimensional gels. (In 2D gels, proteins etc. are separated in one dimension by their charge and in the other dimension by their molecular mass).

The invention is normally to be applied to multiple proteins co-present on the same gel, for example from 3 to 3000, more usually 30 to 3000 and preferably 50 to 1500, proteins. This includes proteins present at different molecular weight separations on a 1D gel or at similar molecular weight separations, but present in parallel lanes or tracks on the 1D gel, as well as those separated by 2D gel electrophoresis. However, the invention also applies to a gel on which a single polypeptide is required to be identified or characterised. In particular, it is useful in relation to immunoblotting of proteins of high molecular weight, e.g. 150-250kDa, in order to split them into fragments in which epitopes can be recognised by immunoblotting.

The first stage of the method of the invention comprises digestion of the proteins within the same gel as that on which they were separated. Within this stage, there are preferably three main operations. The first operation is to dehydrate the gel. The gel may be fully or partially dehydrated depending on the amount of protein digestion required. The greater the dehydration the greater the capacity of the gel subsequently to absorb a solution containing the first polypeptide-cleaving reagent and therefore the greater the digestion. Dehydration may be complete, substantially complete, e.g. by removal of 90-99% by weight of the original water

content, or, more preferably, partial, e.g. by removal of 25-90%, preferably 40-70%, on the same basis. Of course, it is more troublesome to rehydrate a completely dried-out gel. The method of dehydration is not critical.

- 5 Air-drying at ambient temperature, say 15-25°C is preferred. Mere standing of the gel at 4-10°C under low pressure is another method. Air-drying, followed by standing, is a further method.

The next operations are rehydration and the incorporation of the first polypeptide-cleaving reagent in the rehydration buffer. The polypeptide-cleaving reagent is preferably an enzyme such as trypsin or Lys-C, but a chemical cleaving agent such as CNBr could alternatively be used. Examples of other enzymes and chemical cleaving reagents are given later, in connection with the discussion of the second polypeptide-cleaving reagent. Hereinafter enzymes will be referred to, the extrapolation to other polypeptide-cleaving reagents being taken as understood and incorporated *mutatis mutandis* in the following description. The first enzyme may be the same as or different from the second enzyme(s) used in the transblotting step. Any of the enzymes described below for use in transblotting can be used in the full gel digestion.

- 25 In principle, it is immaterial at what stage the first enzyme is introduced into the gel and whether it is present in the gel in a free or immobilised form. However, if present in the gel from the start of electrophoresis, it would normally upset the pattern of protein separation, unless the enzyme or conditions of running the gel were so chosen as to make it inactive while the gel is being run. This could be achieved by adding a reversible inhibitor, of the enzyme to the running buffer. For example, if the enzyme is trypsin a

- 10 -

reversible inhibitor such as benzamidine would be suitable. Conditions are e.g. as described in S. L. Jeffcoate et al., J. Clin. Endocrinol. Metab. 1974 88, 155-157. Then, after the gel has been run, resulting in separation of proteins, it is washed as part of the rehydration step, resulting in the removal of inhibitor and therefore re-activation of the enzyme.

The enzyme is normally added to the gel after isolation of the proteins. It is added as a solution or fine suspension which will penetrate the gel and be absorbed well by the gel solids. In principle, the enzyme could be added before any deliberate step of rehydration or even after rehydration has been effected, e.g. in a concentrated solution. However, in practice, such techniques are unlikely to give the best digestion. Normally, the enzyme will be present in the rehydration solution, which is buffered. Preferably the gel is incubated with the rehydration buffer containing the enzyme, for example for 30 minutes at 35°C. The time and temperature can be varied, according to the size of fragments desired. Rehydration may be partial, complete or even to an extent in which the gel contains more water than when the proteins were run on it. Any extent of rehydration appropriate to allow transblotting is permissible. In practice, it is convenient to treat the gel with excess rehydration solution and to remove the excess. Otherwise, undesired protein diffusion or excessive swelling of the gel can occur.

At this stage the gel contains peptides with a high number of missed cleavages, from partially digested proteins. The fragments of high molecular weight and basic proteins are more easily extractable from the gel by electroblotting, compared with the full molecule.

- 11 -

The second stage of the method of the invention comprises transblotting, preferably electroblotting. Normally, the electroblotting takes place overall in the direction cathode to anode, as the proteins are negatively charged. Depending on the pH of the electroblotting buffer used, positively and negatively charged fragments could be obtained and migrate in opposite directions, towards the cathode and anode respectively. Figures 1 and 2 of the drawings exemplify some sandwiches for the electroblotting. Figure 1 shows an experimental arrangement in which a cathodic collection layer, which is preferably a conventional PVDF membrane, was provided, just to show that under these conditions no proteins migrated to this membrane, despite the alternating field applied (thus reversing the electrodes). It will be understood that under different pH conditions, some fragments could be produced at the cathodic collection layer. Thus, the invention includes the possibility of providing anodic and cathodic collection layers, with hydrophilic membranes interposed between each of them and the separation gel layer. In Figure 1 there is a single hydrophilic membrane, which is preferably a modified PVDF membrane, having an appropriate protein-cleaving reagent, normally a protease enzyme, for example trypsin, immobilised on it, interposed between the gel layer and an anodic collection layer, most conveniently a conventional PVDF membrane, on which the protein fragments are collected. In Figure 2 there is no cathodic collection layer, but there are two consecutive hydrophilic membranes, preferably modified PVDF membranes, each with trypsin immobilised thereon, placed between the gel layer and the anodic collection layer, which, again, is preferably a conventional PVDF membrane.

- 12 -

In more detail, the anode and cathode are separated from the rest of the sandwich by an absorptive layer which soaks up the blotting liquid, while maintaining the liquid in electrical contact with the electrodes, and is conveniently a filter paper. The kinds of electrodes and absorptive layers used in arrangement are not critical and can be any conventionally used in electroblotting.

The anodic collection layer (and cathodic collection layer if used) are also not critical and thus can be any conventional hydrophobic membrane used in electroblotting, such as PVDF (conventional or positively charged), nylon or nitrocellulose, for example.

The "filling" of the sandwich can take the form of one or more membranes (defined as above) sufficiently hydrophilic in character that the proteins and fragments thereof do not tend to stick thereon. This membrane can be formed from any thin member which is porous to the electroblotting liquid and capable of immobilising the polypeptide-cleaving reagent thereon, whether on the surface thereof or within interstices or microcavities therein accessible to the electroblotting liquid (and therefore to the polypeptide to be cleaved). It will typically be from 100 to 600 μm thick. Usually the number of such membranes will be from 1 to 3. With conventional thicknesses of membrane, e.g. 130 to 150 μm as in the preferred "Immobilon AV" PVDF membrane, 2 membranes will frequently be used. They are best placed directly mutually adjacent, i.e. one on top of another. Preferably, the second polypeptide cleaving reagent is bonded to the hydrophilic membrane covalently. For this purpose, the hydrophilic membrane(s) are preferably provided with "active carbonyl" or carboxylic acid groups or derivatives thereof reactive with amino groups present in the cleaving reagent, e.g. an enzyme. "Active

- 13 -

carbonyl"-modified or carboxyl-modified PVDF membranes are especially preferred.

Since it would be difficult to react all the active groups present on the surface of a membrane with an enzyme, and since it is undesirable to allow the polypeptides to react with these free active groups, the residual active groups (which would otherwise be free) are preferably capped before the membrane is used, e.g. with ethanalamine, thus providing terminations such as - CO-NH-CH₂-CH₂-OH, which are relatively hydrophilic. Other hydrophilic capping groups will suggest themselves to those skilled in the art.

Alternatively, PVDF membranes or glass fibre paper can be functionalised by isothiocyanate, which allows reaction with the N-terminal amino groups and/or the ε-amino groups of lysine residues in the enzymes. For this purpose, the PVDF membranes are pre-treated with NaOH to provide a carbon-carbon ethylenic double bond in the polymer chain, by elimination of a molecule of HF. The pre-treated PVDF membranes are then reacted under basic conditions with a dinucleophile such as ethylenediamine, 1,10-diaminodecane or 2-aminoethanethiol, whereby hydrogen atoms in the polymer are substituted by -X-(CH₂)_n-NH₂ groups, wherein -X- is -S- or -NH- and n is 2 or 10. This polymer, having amine-terminated side-chains, is then reacted with 1,4-phenylenediisothiocyanate (DITC) or 3,5-dichloro-1,4-phenylenediisocyanate (DCDITC) to give the required isothiocyanate-terminated side-chains in good yield. DITC-reacted glass fibre sheets provide another form of membrane, see R.H. Aebersold et al., J. Biol. Chem. 1986, 291, 4229-4338.

Another form of hydrophilic membrane is PVDF functionalised by arylamine groups, which react with a

- 14 -

carboxylic acid side-chain or the carboxyl terminus of the enzyme, preferably in the presence of a carbodiimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

Another form of hydrophilic membrane which can be used as the sandwich filling is a thin film or coating of agarose gel. The N-terminal amino and/or ϵ -amino groups (according to the selectivity of the reaction) of lysine residues in the enzyme are treated to obtain aminox groups, which react with aldehyde groups produced by mild oxidation of the agarose gel, thus bonding the enzyme covalently to the agarose.

A further kind of hydrophilic membrane may comprise one or more thin films or coatings of polyacrylamide gel, similar in thickness to that used in immobilised pH gradient electrophoresis (IPG), but which has been trypsinated. This can be done by reacting trypsin with acryloyl chloride to form an N-acryloyl trypsin, which is then copolymerised with acrylamide in the preparation of an acrylamide copolymer gel.

Yet another form of hydrophilic membrane is a glass fibre paper which has been modified to replace amino groups by groups containing a diazo linkage, e.g. 4-N,N-dimethylaminoazobenzene-4'-isocyanate groups. The reactions required for this purpose have been described by J.Y. Chang et al., FEBS Letters 1977, 84, 187-190.

The cleaving reagent immobilised on the membrane is normally and preferably immobilised by covalent bonding. However, other forms of immobilisation are not excluded from use in this invention, so long as the enzyme does not become sufficiently free in solution in the electroblotting liquid as to undergo autodigestion. (It will be understood that the presence of autodigested enzyme fragments could upset the analysis of the fragments from the protein to be analysed). Thus, for

- 15 -

example, the enzyme could be physically trapped within the pores of a porous sheet of hydrophilic polymer. Alternatively, the membrane could have an enzyme immobilised thereon by means comprising (consisting of or including) affinity bonding. Thus, the enzyme could be covalently attached to avidin or streptavidin and the resultant conjugate attached to a biotinylated membrane by affinity bonding between avidin/streptavidin and biotin. Alternatively, avidin or streptavidin could be attached to the membrane and the enzyme could be reacted to provide biotinyl terminations for reaction with a membrane to which avidin or streptavidin has been attached.

Preferably either or both polypeptide-cleaving reagents comprise an enzyme. If both comprise an enzyme, it may be the same or different. Most preferably and usually, the enzyme cleaves the main chain of the polypeptide (i.e. is an endopeptidase or endoproteinase), especially trypsin. Trypsin cuts proteins at the C-terminal end of many lysines and arginines. Other less specific endoproteases, e.g. pepsin or such as chymotrypsin are usable, as are highly specific enzymes such as Lys-C, Arg-C or Glu-C. For phosphoproteins, a phosphorylase is useful. Either or both enzymes can be an exo-enzyme which splits off a side-chain of the protein or acts at the terminus. More than one enzyme can be incorporated in the gel. More than one enzyme can be immobilised on the membrane. For example, it may be helpful to split off one or more side chains of the polypeptide, e.g. using a carboxypeptidase or aminopeptidase, in conjunction with an endoproteinase. Carboxypeptidase Y is one particularly useful such enzyme.

- 16 -

To investigate the presence of side-chains in proteins, such as glucosyl, N-acetyl-O-glucosaminyl and sialyl, enzymes which will cleave those chains, such as glucosidase, N-acetylglucosaminidase and neuraminidase, respectively, are useful in the invention.

The following chart indicates the various possibilities for types of enzymes which may be used in combination:

IFG	OSDT
Endopeptidase, e.g. trypsin	Endopeptidase, e.g. trypsin
Endopeptidase, e.g. trypsin	Exo-enzyme, e.g. glucosidase, phosphorylase
Exo-enzyme, e.g. glucosidase, phosphorylase	Endopeptidase, e.g. trypsin
Exo-enzyme, e.g. glucosidase, phosphorylase	Exo-enzyme, e.g. glucosidase, phosphorylase

The cleaving reagents are not confined to enzymes. Either or both can be a chemical reagent, for example cyanogen bromide, 2-iodosobenzoic acid or a derivative thereof or hydroxylamine. Such reagents are described by E.A.Carrey, "Peptide Mapping" in "Protein Structure: A Practical Approach", ed. T.E.Creighton, IRL Press, 1989, pages 117-121. For use as the second polypeptide-cleaving agent, the chemical reagents are suitably immobilised on the hydrophobic member. Thus, cyanogen bromide can be physically immobilised by entrapment within pores of the hydrophilic membrane. 2-Iodosobenzoic acid can be derivatised, preferably at the COOH group, e.g. with an alkylendiamine, especially 1,6-hexanediamine, leaving a free amino group which is then reacted with functional groups on the membrane, such as active carboxyl groups mentioned above.

It will be appreciated that different cleaving reagents will have different specificities and in certain

- 17 -

cases the absence of small fragments, indicating the absence of cleavage, may be a useful result for identification or characterisation.

The electrical current applied in the electroblotting is preferably not a direct, continuous current, but either pulsed, i.e. a direct current with intervals in which no current is passed, or an alternating current. It may be unbiased or biased in the cathode to anode direction, i.e. mainly a cathode to anode current, but with intervals in which current is passed in the opposite direction. Variations on these regimes are possible within the general spirit of the idea of performing a slower than normal electroblotting, allowing sufficient time for the cleavage to take place on the hydrophilic membrane(s), while avoiding such a slow journey of the protein fragments from the separation gel to the collection membrane that lateral diffusion occurs, causing loss of resolution.

The electroblotting liquid is not critical to obtaining some form of protein fragmentation and hence a useful identification. It is normally buffered and can be any conventional buffer for this purpose, such as Tris/glycine with methanol or 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS) with methanol. The direction of migration of the fragments depends essentially on the pH of the buffer. For most purposes an alkaline buffer will be appropriate, since many enzymes function best at alkaline pH. Particularly, in the case of trypsin, the buffer will preferably have a pH from 8.0 to 9.0 and most especially 8.2 to 8.6, with a half Towbin's buffer of pH about 8.4 being considered optimal. Some other enzymes, such as endoproteinase V8, require an acidic pH. Under such conditions, the fragments will migrate to the cathode.

- 18 -

It has been found desirable to incorporate a small amount of a conventional detergent such as SDS in the buffer, to produce micelles (negatively charged aggregates).

5 The protein fragments, whether they are peptides derived from the main chain of the protein or are residues of a side-chain, are collected on the collection layer. They are then preferably analysed by a spectroscopic method based on matrix-assisted laser desorption/ionisation (MALDI) or electrospray ionisation (ESI). The preferred procedure is MALDI with time of flight (TOF) analysis, known as MALDI-TOF MS. This involves forming a matrix on the membrane, e.g. as described in the literature, with an agent which absorbs 10 the incident light strongly at the particular wavelength employed. The sample is excited by UV, or IR laser light into the vapour phase in the MALDI mass spectrometer. Ions are generated by the vaporisation and form an ion plume. The ions are accelerated in an electric field and separated according to their time of travel along a given distance, giving a mass/charge (m/z) reading which is very accurate and sensitive. MALDI spectrometers are 15 commercially available from PerSeptive Biosystems, Inc. (Framingham, MA, USA) and are described in the literature, e.g. M.Kussmann and P. Roepstorff, cited above.

20

25

In this invention, the above method is applied to the scanning of the fragments of many proteins at once. Thus, many proteins can be run simultaneously on a 30 polyacrylamide gel, subjected to the method of the invention to produce an array of spots on the collecting membrane and the array analysed as follows. After the PVDF membrane or other hydrophobic collection layer has been stained, a piece of it will be cut and fixed on the

MALDI-MS sample plate, e.g. with silicon grease. An organic matrix-forming reagent is added to the membrane on the sample plate and the sample is then air-dried to form the matrix. The sample plate is inserted in the
5 MALDI-MS spectrometer. An automated movement of the sample plate from a first to a second position and subsequent positions, to align the laser with individual spots in the array, is arranged by computer program. At each position a MALDI-MS spectrum is generated, the
10 spectral information collected in digital form and the data downloaded to the ExPASy database research program (PeptIdent).

It is then relatively simple to provide automated output of the results by using the ExPASy server, as at
15 present used for MALDI-TOF MS and to generate the data in a form handleable by computers.

It will be evident, therefore, that the present invention has huge potential for the automated identification and/or partial characterisation of
20 proteins, e.g. in proteomics research. In effect, the invention provides in this preferred embodiment a "molecular scanner" for this purpose.

Other techniques for improving the mass accuracy and sensitivity of the MALDI-TOF MS can be used to analyse
25 the fragments of protein obtained on the collection membrane. These include the use of delayed ion extraction, energy reflectors and ion-trap modules. In addition, post source decay and MS-MS analysis are useful to provide further structural analysis. With ESI, the
30 sample is in the liquid phase and the analysis can be by ion-trap, TOF, single quadrupole or multi-quadrupole mass spectrometers. The use of such devices (other than a single quadrupole) allows MS-MS or MS^n analysis to be performed.

- 20 -

Still other methods of analysis comprise immunoblotting using monoclonal or polyclonal antibodies and phospho-imaging.

Optionally, other components may be included in the kit, especially any one or more of the following: matrix-forming reagent for MALDI-TOF, rehydration buffer, electroblotting buffer, collection layer(s), e.g. cationic membranes and PAGE materials. In the case of immunoblotting, the kit may further comprise one or more antibodies, especially a range of monoclonal antibodies. Kits as defined above, but further comprising any one, two or more of the above optional components are hereby specifically declared to be within the invention. All components of the kit may be supplied in separate containers, but packaged overall as a kit.

The following Examples illustrate the invention. The words "Immobilon", "Trans-Blot", "Trizma", "Tween" and "Voyager" are Trade Marks and/or Registered Trade Marks.

EXAMPLES

Materials and methods

Chemicals. "Immobilon" type AV (IAV) membranes were purchased from Millipore (Bedford, MA, USA). Acrylogel-PIP 2.6%C solution was purchased from BDH (Poole, England). Broad range SDS-PAGE standard PVDF membranes were purchased from Bio-Rad (Richmond, CA, USA). Trifluoroacetic acid (TFA), "Trizma base" (Tris), 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS) and trypsin (type IX from porcine pancreas, dialysed and lyophilised) were purchased from Sigma (St. Louis, MO, USA). Acetonitrile (preparative HPLC grade), calcium chloride, ethanolamine, glycine and α -tosyl-L-arginine methyl ester (TAME) were purchased from Fluka (Buch, Switzerland).

- 21 -

12.5%, 2.6% C linear gel (home made). To produce a
12.5% T, 2.6% C linear polyacrylamide gel, crosslinked
with PIP ("PIP" = N,N'-diacryloylpiperazine), 8 ml of
5 Acrylogel-PIP 2.6%C stock solution were mixed with 5 ml
of Tris-HCl 1.5 M pH 8.8 and 6.6 ml of deionised water.
The polymerisation of the gel was induced with 20 µl of
10 TEMED and 100 µl of APS (10% w/v). The solution was
degassed and loaded into a Bio-Rad mini-2D gel support.
To preserve the gel from the atmosphere, 0.5 ml of water-
saturated sec-butanol was added on the top of the gel.
After 30 minutes, the gel was washed for subsequent
loading of the 4% stacking gel. It was obtained from the
mixture of 2.6 ml Acrylogel-PIP 2.6%C stock solution, 5
ml of Tris-HCl 1.5 M, pH 8.8, 12.3 ml of deionised water,
15 20 µl of TEMED and 100 µl of APS (10% w/v). The solution
was degassed and loaded on top of the gel. A comb was
inserted before gel polymerisation to create 15 sample
wells. The gel can be used directly after 30 minutes of
polymerisation.

20 1-D PAGE. For the 1-D PAGE method, Mini-Protean II
electrophoresis apparatus (Bio-Rad, Richmond, CA, USA)
was used. SDS-PAGE was conducted essentially according to
the method of Laemmli, with 12.5%T, 2.6%C polyacrylamide
gel. The protein samples used were Bio-Rad SDS-PAGE
25 standards. They were bovine pancreatic trypsin inhibitor
(6.5 kDa), chicken lysozyme (14.3 kDa), soybean trypsin
inhibitor (20.1 kDa), bovine carbonic anhydrase (28.9
kDa), chicken ovalbumin (42.7 kDa), bovine serum albumin
(66.4 kDa), and rabbit phosphorylase b (97.2 kDa),
30 E.coli. β-galactosidase (116.4 kDa) and rabbit myosin
(about 200 kDa). Protein migration was carried out on a
single lane at 200 V for 40-50 minutes.

Covalent attachment of trypsin and blockage of the
IAV membrane. IAV membrane is a commercially available

modified PVDF membrane, having activated carboxylated groups. These groups are reactive towards nucleophiles such as amine groups from proteins or peptides. Based on the above-cited Millipore technical documentation on
5 "Immobilon AV", trypsin was immobilised on this membrane (Figure 1).

A 10 x 12 cm IAV membrane was incubated in a rotating hybridiser HB-2D (Techne, Cambridge, England) with 20 ml of a 2.5 mg/ml trypsin solution in 20 mM sodium dihydrogen phosphate buffer, pH 7.8, at room temperature for 3 hours. Then, the membrane was washed 3 times rapidly and vigorously with 20 ml of PBS-''Tween'' 20 solution (20 mM of sodium dihydrogen phosphate, 140 mM sodium chloride and 0.5% ''Tween'' 20, pH 7.4) to remove unreacted trypsin. The membrane was incubated for 3 hours with 20 ml of 1M ethanolamine in 1M sodium bicarbonate, pH 9.5, at 4°C to block the remaining active carboxyl groups of the membrane. After this capping step, the membrane was washed 3 times rapidly and vigorously with 20 ml of the PBS-''Tween'' solution and then twice for 30 minutes with 20 ml of the PBS-''Tween'' solution. The membranes were stored at 4°C in a 46 mM Tris-HCl, 1.15 mM calcium chloride, 0.1% sodium azide buffer solution, pH 8.1.

25 Activity measurement of the enzyme covalently bound to the IAV membrane. The tryptic activity of the IAV-Trypsin membrane was determined using the trypsin assay reagent TAME. One to 2 cm² of the IAV-trypsin membrane was immersed in a mixture of 2.6 ml of 460mM Tris-HCl, 30 11.5mM calcium chloride, pH 8.1, 0.3 ml of 10 mM TAME solution and 0.1 ml of 1mM HCl solution. After 40 seconds of vigorous stirring, the absorbance of the solution was measured at 247 nm with a UV-Visible spectrophotometer (Ultrospec III, Pharmacia Biotech, Uppsala, Sweden). A

- 23 -

second measurement was made after 3 minutes of constant stirring. The equivalent amount of free active trypsin per surface unit was calculated from the change per minute in optical absorbance at 247 nm.

- 5 In full gel (IFG) protein digestion and conventional electroblotting (for comparison). Immediately after the SDS-PAGE protein separation, the gels were soaked 3 times in deionised water for 5 minutes to eliminate SDS, glycine and Tris. The entire wet gel or a selected part
10 of it was air dried at room temperature during 8 hours or overnight. The gel was rehydrated and incubated at 35°C for 30 minutes with 3-5 times the initial volume of the gel of a solution of 0.05 mg/ml trypsin in 10 mM Tris-HCl, pH 8.2. The excess of trypsin solution was removed.
15 Then, the gel was incubated for a further 30 minutes at 35°C to complete the digestion. Proteins and peptides contained in the gel were electroblotted onto PVDF membranes using standard procedure with CAPS buffer, pH 11, 0.01% SDS in the tank.
20 One-step digestion transfer (OSDT) electroblotting (for comparison). Immediately after the SDS-PAGE protein separation, gels were soaked 3 times in deionised water for 5 minutes, and then equilibrated for 15 minutes in half Towbin's buffer (13 mM Tris, 100 mM glycine, 0.01%
25 SDS, 10% methanol, pH 8.3). Electroblotting was carried out in half Towbin's buffer in a laboratory-made semi-dry apparatus. [Note: the "semi-dry" method is well known, see e.g. P. R. Fausset and H. S. Lu, Electrophoresis 1991, 12, 22-27.] It was carried out for 16 hours at
30 room temperature (21 to 24°C), with a square-shape alternating applied voltage, periodically +12.5 V for 125 ms and -5 V for 125 ms. The shape of the applied voltage is shown in Figure 3, in which voltage is plotted on the

- 24 -

y-axis and time in milliseconds on the x-axis. The average effective voltage $U_{eff} = 3.75V$ and is given by the identity

$$U_{eff} = \frac{1}{T} \times [\text{Integral between } 0 \text{ and } T \text{ of } U dt]$$

5

where U is the voltage at a particular timepoint, dt is the change in time between the limits of the integration and T is the total time of one cycle or period = 250 ms.

To perform the enzymatic digestion of the protein during the electroblotting, a double layer of IAV-trypsin membrane was placed between the polyacrylamide gel as a protein source and the PVDF membrane as the collecting surface to create a transblot-digestion sandwich (Figures 1 and 2).

15 After the electroblotting transfer procedure, the PVDF collection membranes, i.e. on which the fragments of digested protein were collected, were washed in deionised water for 5 to 15 minutes. Proteins remaining in the gel after the electroblotting were stained with 20 Coomassie Blue R250 (0.1% w/v), methanol (30% v/v) and acetic acid (10% v/v) for 30 minutes. Gels were destained by repeated washing with methanol (40% v/v), and acetic acid (10% v/v) solution. The PVDF collection membranes were stained with Amido Black (0.5% w/v), isopropanol 25 (25% v/v) and acetic acid (10% v/v) for 1 minute and then destained by repeated washing with deionised water. The membranes were air-dried before optical scanning.

IFG/OSDT electroblotting (combined method of the invention). In the combined method, the IFG procedure 30 was modified by allowing only the first 30 minutes for rehydration and partial protein digestion. The gel was then transblotted onto PVDF membrane using the OSDT process described above. The electroblot transfer was

- 25 -

carried out in half Towbin's buffer containing 0.01% SDS, as described above.

MALDI-TOF equipment and experimental conditions.

PVDF membranes were analysed with a MALDI-TOF mass spectrometer "Voyager" Elite (PerSeptive Biosystems, Framingham MA, USA) equipped with 337 nm nitrogen laser. The analyser was used in the reflectron mode at an accelerating voltage of 18 kV, a delay of ion extraction of 100 ns and a low mass gate fixed at 850 Da. Laser power was set slightly above threshold for molecular ion production. Spectra were obtained by summation of 10 to 256 consecutive laser shots without any smoothing procedure. Small pieces of the PVDF (1 x 3 mm square) containing the stained protein were cut from the PVDF collection membrane and fixed on an adaptable sample MALDI plate with silicon grease. For deposition of the matrix required for MALDI-TOF MS, 1 µl of 4 mg/ml α-cyano-4-hydroxycinnamic acid in 30% acetonitrile, 0.1% TFA solution was added to the anodic PVDF membrane. For the internal calibration, the matrix solution contained 20 nM and 100 nM respectively of two C-amidated synthetic peptides of molecular weights 1498.82 Da and 2095.08 Da.

Treatment of spectra and use of software.

Detected peaks were submitted to the peptide mass fingerprint search tool "PeptIdent" available on the World Wide Web (<http://www.expasy.ch/www/tools.html>) located at the ExPASy server (<http://www.expasy.ch>). No pI limits were introduced to restrict the search. The apparent migration masses given by the Bio-Rad technical information sheet were used as a restricted condition on the mass value with an error of 20%, as well as the specie origin of the protein. Mass tolerance was ±0.2 Da.

- 26 -

Fragment masses were submitted to "FindMod" (<http://www.expasy.ch/www/tools.html>) to identify the amino acid sequence of fragments from their spectral molecular weights. FindMod has options to take into account possible cysteine and methionine modifications of proteins.

Results

Trypsin was attached covalently to IAV membranes with a surface enzyme density, as determined by TAME test, of 0.6 to 1.2 µg of active trypsin per cm². The activity of the trypsin-bound IAV membranes remained stable when they were stored in the Tris-HCl/CaCl₂/NaN₃ solution at 4°C for periods up to a month. Tryptic activity decreased slightly after use of the membrane in the method of the invention, but not sufficiently to impair its re-use in another experiment.

After SDS-PAGE separation, the nine proteins specified above, were run on the same track in the SDS-PAGE, were subjected to a control electroblotting plus three different digestion techniques:

- Control electroblotting of the proteins in the tank method, without digestion, using the standard CAPS buffer, pH 11,
- IFG digestion followed by electrotransfer using the tank method with CAPS buffer,
- OSDT digestion through IAV membrane using a semi-dry method and the half Towbin's buffer, pH 8.3,
- Combined method of the invention (partial IFG followed by OSDT).

Figures 4A to 4D show the transblot pattern of the four Amido Black stained PVDF membranes corresponding to a control without digestion (A), IFG digestion (B), OSDT (C) and the combined method of the invention (D), with the molecular weights of the nine proteins indicated.

- 27 -

Figures 5A to 5D show the pattern of the proteins remaining on the SDS gel.

First, protein transfer using OSDT with half Towbin's buffer, 0.01% SDS, pH 8.4 (Figure 4C) can be compared with the standard transfer using CAPS buffer, 0.01% SDS, pH 11 (Figure 4A). Despite the addition of SDS in the $\frac{1}{2}$ Towbin's buffer, basic proteins such as pancreatic trypsin inhibitor (pI 9.2) and lysozyme (pI 9.3) did not transfer. The influence of the SDS in the buffer was more noticeable for higher molecular weight proteins such as phosphorylase b (97.2 kDa) and myosin (≈ 200 kDa) (Figures 4A and 4C). However, large amounts of these proteins remained in the gel after the electroblot (Figures 5A and 5C).

In the case of the IFG digestion (Figure 4B) and the combined method (Figure 4D), the PVDF membrane exhibited all of the 9 protein bands. PVDF patterns were similar to the normal transfer (Figure 4A). The major difference between these PVDF membranes was that the intensity of the polypeptide beads was higher for normal protein transfer (Figure 4A) and lower for the combined method (Figure 4D). This should not be interpreted that the combined method of the present invention provided an inferior result as it should be noted that the digestion of proteins can modify their staining properties. Proteins remaining in the gel were very low in both IFG and combined methods (Figures 5B and 5D).

In a second experiment, these samples were analysed with MALDI-MS for peptide mass fingerprinting detection.

The results of these tests are summarised in Table 1. Recent results based on the OSDT process had previously highlighted the problems pointed out above, relating to partial transblot of basic and high molecular weight proteins. In this case, no identification could

- 28 -

be obtained for lysozyme (pI 9.2) and pancreatic trypsin inhibitor (pI 9.3) as well as myosin (MW \approx 200 kDa). The IFG digestion technique was not sufficient to obtain enough peptides to identify correctly most of the proteins. The combination method of partial IFG followed by OSDT provided overall the best results in terms of protein identification. All of the 9 proteins were identified and that despite the high pI of a lysozyme (see MALDI-MS spectra in Figs. 6A-6C) and high molecular weight of a myosin (see MALDI-MS spectra in Figs. 7A-7C) of the analysed proteins. Figures 6A, 7A relate to OSDT, 6A, 7B to IFG digestion and 6C, 7C to the combined method of the invention. Note in the combined procedure the greater number of fragments generated and the greater fragmentation of the marker proteins of m.w. 1498.82 and 2095.08 used for internal calibration.

0
40
30
20
10
-10
-20
-30
-40

- 29 -

Table 1

Protein name	pI ¹	MW (kDa) ¹	OSDT		IFG		Combined	
			No. Pept ²	Prot Id ³	No. Pept ²	Prot Id ³	# of Pept ²	Prot Id ³
Bovine pancreatic trypsin inhibitor	9.2 4	6.5	0	-	1	-	4	+
Chicken lysozyme	9.3	14.3	0	-	2	-	7	+
Soybean trypsin inhibitor	4.6	20.1	7	+	1	-	7	+
Bovine carbonic anhydrase	7.9	29.0	9	+	0	-	4	+
Chicken ovalbumin	5.2	42.8	7	+	4	-	5	+
Bovine serum albumin	5.6	66.4	4	+	3	-	12	+
Rabbit Phosphor-ylase b	6.8	97.2	12	+	1	-	17	+
E.coli β-Galactosidase	5.3	118.1	20	+	7	+	19	+
Rabbit myosin ⁴	--	223	0	-	2	-	10	+
% Ident-ification	--	--	--	67%		11%		100%

- 30 -

- 1 pI and molecular weight were calculated with the
"Compute pI/Mw" tool (available on the ExPASy
server)
- 2 Number of peptides identified that correspond to
5 correct enzymatic residue-specific fragments of the
protein under test (determined with FindMod tool)
- 3 +/-: Correct/incorrect identification of the protein
using the peptide mass fingerprints obtained from
MALDI-MS spectra, as determined by PeptIdent
10 (Available on the ExPASy server)
- 4 Myosin was correctly identified from rabbit skeletal
muscle, using the TREMBL database
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Thus, it has been shown that the method of the present invention can identify proteins having a wide range of pI value and molecular weight. First, trypsin digested proteins in the gel without restriction of mass and/or pI. This step resulted in peptides of high average molecular weight corresponding to several missed cleavage, but their lower molecular weights were lower than that of the original protein. For a few peptides, pI and hydrophobicity were also lower than for the entire protein. Secondly, these peptides were easily extracted by electroblotting and digested again during the OSDT procedure. The method gave good mass spectra and subsequent identification for 9 out of 9 analysed proteins.

The myosin protein referred to above cannot be immunoblotted by conventional methods, even when using CAPS buffer with 0.01% SDS. However, it can be immunoblotted by the above-described transblotting procedure. By use of a monoclonal antibody, myosin can be detected on the PVDF membrane.

Each of the above-mentioned publications is herein incorporated by reference to the extent to which it is relied on herein.

CLAIMS

1. A kit comprising:

a) a first polypeptide-cleaving reagent suitable for incorporating in an electrophoretic gel;

5 b) at least one hydrophilic membrane suitable for use in transblotting of polypeptides separated on an electrophoretic gel, the membrane having at least one second polypeptide-cleaving reagent immobilised thereon; and

10 c) a hydrophobic collection member suitable for receiving thereon fragments of the separated polypeptides transferred thereto by transblotting.

2. The kit of Claim 1, wherein the hydrophilic membrane and hydrophobic collection member are provided as a pre-formed assembly.

15 3. The kit of Claim 1 or 2, wherein the second polypeptide-cleaving reagent is immobilised on the hydrophilic membrane by covalent bonding.

4. The kit of Claim 3, wherein the second polypeptide-cleaving reagent is immobilised through an amide linkage formed between (1) the functional groups on the hydrophilic membrane selected from the group consisting of activated carbonyl groups, carboxylic acid groups and carboxylic acid derivative groups capable of reacting 25 with an amino group, and (2) an amino group of the polypeptide-cleaving reagent.

5. The kit of Claim 1, 2, 3 or 4, wherein the polypeptide-cleaving reagents are enzymes, which may be the same or different.

30 6. The kit of Claim 5, wherein each enzyme comprises a protease.

7. The kit of Claim 6, wherein the protease comprises trypsin.

- 33 -

8. The kit of Claim 1, 2, 3, 4, 5, 6 or 7, further comprising:

d) a buffer suitable for at least partially rehydrating a gel on which at least one polypeptide has been isolated and which has been dehydrated.

5 9. The kit of Claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein the hydrophobic collection member is a self-supporting membrane.

10 10. A method of identifying or characterising polypeptides which have been isolated on a gel by electrophoresis, comprising the steps of:

a) providing a gel on which at least one polypeptide has been isolated;

b) incorporating a first polypeptide-cleaving reagent in the gel;

c) providing adjacent to the gel at least one hydrophilic membrane on which is immobilised at least one second polypeptide-cleaving reagent;

d) providing a hydrophobic collection member suitable 20 for receiving thereon fragments of polypeptide transferred thereto from the gel by transblotting, said hydrophobic layer being positioned beyond the hydrophilic membrane in a direction of movement of the fragments of polypeptide;

e) transblotting the polypeptides from the full gel, on which the polypeptide or polypeptides were isolated, through the hydrophilic membrane or membranes, under conditions effective to cause them to be cleaved into fragments by the second polypeptide-cleaving reagent, to 25 the hydrophobic layer; and

f) identifying or characterising the fragments collected on the hydrophobic collection member.

30 11. The method of Claim 10, which further comprises:

- 34 -

g) identifying or characterising the polypeptide from which the fragments were derived.

12. The method of Claim 10 or 11, wherein the first polypeptide-cleaving reagent is incorporated in the gel by dehydrating the gel and then at least partially rehydrating it with a buffer containing the polypeptide-cleaving reagent.

5 13. The method of Claim 10, 11 or 12, wherein the immobilisation of the second polypeptide-cleaving reagent is by covalent bonding thereof to the hydrophilic membrane.

10 14. The method of Claim 10, 11, 12 or 13, wherein both the polypeptide-cleaving reagents are enzymes, which may be the same or different.

15 15. The method of Claim 14, wherein either or both enzymes cleave the polypeptide in its main chain.

16. The method of Claim 14, wherein either or both enzymes cleave the polypeptide in a side-chain thereof.

20 17. The method of Claim 14, wherein both enzymes are trypsin and the electroblotting is carried out in a buffer of pH from 8 to 9.

25 18. The method of Claim 10, 11, 12, 13, 14, 15, 16 or 17, wherein the voltage at which the electroblotting is carried out is adjusted to provide a slower than normal transfer, so as to extend the residence time of the polypeptide in the proximity of the cleavage reagent.

19. The method of Claim 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the electroblotting is carried out under conditions which provide either (1) a discontinuous 30 current from anode to cathode or (2) an alternating current biased in the anode to cathode direction.




20. The method of Claim 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19, wherein the fragments are identified by mass spectrometry.

- 35 -


21. The method of Claim 20, wherein the membrane is
scanned directly by matrix-assisted laser
desorption/ionisation time of flight spectrometry and the
data obtained therefrom compared with a database, using a
5 computer program, to provide automated polypeptide
identification.

SEARCHED
INDEXED
COPIED
FILED


1/9

Fig. 1*Fig. 2**Fig. 3*

2/9




3/9




4/9

Fig. 6A
IFG digestion




5/9

Fig. 6B
OSDT process




6/9

Fig. 6C*Combined method*


7/9

Fig. 7A
IFG digestion




8/9

Fig. 7B
OSDT process



9/9

Fig. 7C
Combined method



Docket No.
UDG,002-PCT-US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD AND KIT FOR IDENTIFYING OR CHARACTERISING POLYPEPTIDES

the specification of which

(check one)

is attached hereto.
 was filed on 27th January 2000 as United States Application No. or PCT International Application Number PCT/EP00/00689
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority	Not Claimed
UK99 01775.8 (Number)	UK	<input type="checkbox"/>
UK99 07790.1 (Number)	(Country) UK	<input type="checkbox"/>
	(Day/Month/Year Filed) 28th January 1999	<input type="checkbox"/>
	(Day/Month/Year Filed) 7th April 1999	<input type="checkbox"/>
	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.





POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

ANDREW T. KARNAKIS - Reg. No. 27,909

Send Correspondence to: Applied Biosystems - Attn Andrew T. Karnakis
500 Old Connecticut Path
Framington, MA 01701

Direct Telephone Calls to: (name and telephone number)
ANDREW T. KARNAKIS - (508) 383 7406

Full name of sole or first inventor <u>Willy Vincent BIENVENUT</u>		20.06.2001
Sole or first inventor's signature		Date
Residence <u>Thenac, France</u>		
Citizenship <u>FR</u>		
Post Office Address <u>4 Route des Mauds</u>		
<u>F-17460 Thenac, France</u>		

Full name of second inventor, if any <u>Denis Francois HOCHSTRASSER</u>		20.6.2001
Second inventor's signature		Date
Residence <u>Geneva, Switzerland</u>		
Citizenship <u>CH</u>		
Post Office Address <u>Chemin de la Savonniere</u>		
<u>Collonge-Bellerive, CH-1245 Geneva, Switzerland</u>		

3-00

Full name of third inventor, if any
Jean-Charles SANCHEZ

Third inventor's signature

21-06-01

Date

Residence
Geneva, Switzerland

Citizenship
CH

Post Office Address
Chemin Frank-Thomas 42

CH-1208 Geneva, Switzerland

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address